Physitrack aims to achieve annual organic sales growth exceeding 30% in the medium term, further supplemented by impact from future add-on acquisitions.
Physitrack targets an EBITDA margin of 40-45% in the medium term, with potential short term margin contractions due to add-on acquisitions impacting margins.
Physitrack aims to reinvest profits and cash flows in organic growth initiatives and add-on acquisitions to support further value creation, and therefore, does not expect to pay dividends in the medium term.
Physitrack’s financial targets stated above constitute forward-looking information. The financial targets are based upon a number of estimates and assumptions relating to, among others, the development of Physitrack’s industry, business, result of operations and financial position, and are subject to risks and uncertainties.